Drug development – Page 20

GLP readiness concerns during IND-enabling studies – CAPA for study design gaps

Addressing GLP Readiness Concerns in IND-Enabling Studies: A Comprehensive CAPA Investigation The journey from drug discovery to clinical trials is fraught with challenges, not least of which are Good Laboratory…

Non-clinical toxicity findings during regulatory submission prep – how to defend preclinical package

Addressing Non-clinical Toxicity Findings During Regulatory Submission Preparation In the realm of pharmaceutical development, encountering non-clinical toxicity findings during the preparation of regulatory submissions can pose significant challenges. These findings,…

Non-clinical toxicity findings during IND-enabling studies – preventing clinical hold

Addressing Non-Clinical Toxicity Findings to Prevent Clinical Holds in IND-Enabling Studies Non-clinical toxicity findings during Investigational New Drug (IND)-enabling studies often introduce considerable risk during the drug development process. Identifying…

GLP readiness concerns during regulatory submission prep – how to defend preclinical package

Addressing GLP Readiness Issues During Regulatory Submissions The successful transition from preclinical studies to regulatory submissions hinges on thorough preparation, particularly regarding Good Laboratory Practice (GLP) readiness. Issues in this…

Reproducibility gaps during IND-enabling studies – CAPA for study design gaps

Addressing Reproducibility Challenges in IND-Enabling Studies: A Systematic Investigation The increasing complexity of drug discovery has heightened scrutiny on reproducibility within IND-enabling studies. These studies serve as foundational components, influencing…

Dose justification weak during study audit – preventing clinical hold

Understanding Weak Dose Justification During Study Audits to Prevent Clinical Holds In the pharmaceutical industry, a weak dose justification can lead to significant regulatory challenges, particularly during study audits. Such…

Dose justification weak during program hold risk review – how to defend preclinical package

Addressing Weak Dose Justification During Program Hold Risk Review in Preclinical Packages In the realm of pharmaceutical research and drug development, particularly during preclinical studies, the integrity of dose justification…

Species selection questioned during regulatory submission prep – regulatory deficiency risk analysis

Analyzing Species Selection Issues in Regulatory Submission Preparation In the realm of pharmaceutical research and drug development, the selection of appropriate animal species during preclinical studies is pivotal. Regulatory agencies…

Non-clinical toxicity findings during sponsor oversight – CAPA for study design gaps

“`html Addressing Non-Clinical Toxicity Findings During Sponsor Oversight: A Root Cause Investigation Approach The emergence of non-clinical toxicity findings during sponsor oversight can significantly derail drug development timelines, creating challenges…

Species selection questioned during sponsor oversight – CAPA for study design gaps

In-Depth Investigation of Species Selection Concerns in Sponsor Oversight and Its CAPA In the landscape of pharmaceutical research, the selection of animal species during preclinical studies is critical to ensure…

Dose justification weak during program hold risk review – CAPA for study design gaps

Addressing Weak Dose Justification in Program Hold Risk Reviews: An Investigative Approach Pharmaceutical professionals often encounter challenges during preclinical research, particularly regarding dose justification within program hold risk reviews. When…

Dose justification weak during regulatory submission prep – regulatory deficiency risk analysis

Weak Dose Justifications During Regulatory Submission Prep: An Investigative Approach The preparation of regulatory submissions, particularly those concerning dose justification, is a critical phase in the drug development process. A…